CRVSCorvus Pharmaceuticals, Inc.
$10.52+79% 1Y
$10.52
$6.0452 weeks$25.52
CRVS in its own filings
CRVS's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
210
Events found in the filings · across 581 filings · the record starts in 2015
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 8-K
- Record starts
- Dec 7, 2015
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- Delisting notice / listing-rule failurehistorical
- 2022-10-28
- SEC comment-letter activity16 occurrences
- 2024-08-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 22, 2026On July 21, 2026, Ian T. Clark delivered notice of his intention to resign from the board of directors (the “Board”) of Corvus Pharmaceuticals, Inc. (the “Company”), effective as of July 22, 2026.Director or officer change · Form 8-K
- May 14, 2026The trial enrolled 72 patients with moderate-to-severe atopic dermatitis that previously failed one prior topical or systemic therapy. Thirty-five percent of the patients had received a prior systemic therapy.Regulation FD disclosure · Form 8-K
- May 7, 2026Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results.Earnings release · press release
- Apr 23, 2026On April 22, 2026, the Board of Directors (the “Board”) of Corvus Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Andrew C. Chan, M.D., Ph.D., to the Board, effective April 23, 2026.Director or officer change · Form 8-K
- Mar 12, 2026Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
- Jan 23, 2026On January 21, 2026, Corvus Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Goldman Sachs & Co. LLC, as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to …Other event · Form 8-K
- Jan 20, 2026On January 20, 2026, in connection with the proposed registered underwritten public offering, Corvus Pharmaceuticals, Inc. (the “Company”) notified Jefferies LLC (“Jefferies”) that it has suspended the offering of any shares of its common stock, par value $0.0001 per share, pursuant to the prospectus supplement filed …Other event · Form 8-K
- Jan 20, 2026Based on the encouraging results from cohorts 1-3, cohort 4 was prospectively designed to support and potentially extend the clinical results obtained in the initial cohorts.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks